Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022
November 16, 2022 10:00 ET
|
Nykode Therapeutics
OSLO, Norway, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer
November 07, 2022 10:30 ET
|
Nykode Therapeutics
OSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to present at two upcoming investor conferences in November
November 07, 2022 02:00 ET
|
Nykode Therapeutics
OSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
October 26, 2022 10:30 ET
|
Nykode Therapeutics
VB10.NEO induced a T cell response in 95% of the patients, including expansion of both novel and pre-existing T cells The responses were broad, and the majority of the encoded neoepitopes were...
Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate
September 27, 2022 00:45 ET
|
Nykode Therapeutics
Nykode’s vaccine candidate boosted Spike-specific T cell responses and induced de novo T cell responses to non-Spike antigens found across SARS-CoV-2 variantsNykode’s Vaccibody technology combined...
Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference
September 09, 2022 11:00 ET
|
Nykode Therapeutics
OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022
August 22, 2022 00:45 ET
|
Nykode Therapeutics
OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange
June 16, 2022 03:00 ET
|
Nykode Therapeutics
OSLO, Norway, June 16, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
Nykode Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2022 02:00 ET
|
Nykode Therapeutics
OSLO, Norway, June 01, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer
May 09, 2022 00:45 ET
|
Nykode Therapeutics
VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer VB10.16 in...